News & Events

Savara Pharmaceuticals / News & Events
19Mar, 2017

Mast Therapeutics sets date for special meeting of stockholders to vote on proposed merger with Savara

0 Comments
Special Meeting To Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX – March 16, 2017 –... Read More
07Jan, 2017

Mast Therapeutics and Savara sign merger agreement

0 Comments
Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled... Read More
02Nov, 2016

Savara Pharmaceuticals appoints David L. Lowrance as CFO

0 Comments
Austin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
18Jul, 2016

Savara Completes Acquisition of Serendex

0 Comments
Strengthens pipeline serving patients with rare respiratory diseases Austin, Texas – July 18, 2016 – Savara Pharmaceuticals, an emerging specialty... Read More
21Jun, 2016

Savara Pharmaceuticals Acquires Serendex Pharmaceuticals

0 Comments
Adds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 Savara Pharmaceuticals, an emerging specialty... Read More
09Jun, 2016

Savara Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

0 Comments
New York City – June 9, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
25May, 2016

First patient dosed in Savara’s pivotal trial for PAP

0 Comments
Savara’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its... Read More
12May, 2016

Savara signs license agreement with Japanese partner

0 Comments
Savara signs license agreement with Japanese Nobelpharma Co. Ltd for future commercialisation of Molgradex® in Japan. With reference to earlier... Read More
01Mar, 2016

Savara Pharmaceuticals Completes $20 Million Round of Financing

0 Comments
Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX –... Read More
23Feb, 2015

Savara Pharmaceuticals’ AeroVanc Meets Primary Endpoint of MRSA Reduction in Phase 2 Trial in People with Cystic Fibrosis

0 Comments
Trial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 Savara Pharmaceuticals announced today positive... Read More
Back to Top